- Home
- SILO vs RNAZ Comparison
SILO vs RNAZ Comparison
Compare SILO & RNAZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SILO
- RNAZ
- Stock Information
- Founded
- SILO 2010
- RNAZ 2016
- Country
- SILO United States
- RNAZ United States
- Employees
- SILO N/A
- RNAZ N/A
- Industry
- SILO Apparel
- RNAZ Biotechnology: Pharmaceutical Preparations
- Sector
- SILO Consumer Discretionary
- RNAZ Health Care
- Exchange
- SILO Nasdaq
- RNAZ Nasdaq
- Market Cap
- SILO 4.7M
- RNAZ 4.9M
- IPO Year
- SILO N/A
- RNAZ 2021
- Fundamental
- Price
- SILO $1.96
- RNAZ $3.35
- Analyst Decision
- SILO
- RNAZ Strong Buy
- Analyst Count
- SILO 0
- RNAZ 1
- Target Price
- SILO N/A
- RNAZ $20.00
- AVG Volume (30 Days)
- SILO 9.0M
- RNAZ 143.7K
- Earning Date
- SILO 02-14-2025
- RNAZ 11-14-2024
- Dividend Yield
- SILO N/A
- RNAZ N/A
- EPS Growth
- SILO N/A
- RNAZ N/A
- EPS
- SILO N/A
- RNAZ N/A
- Revenue
- SILO $72,102.00
- RNAZ N/A
- Revenue This Year
- SILO $1.86
- RNAZ N/A
- Revenue Next Year
- SILO N/A
- RNAZ N/A
- P/E Ratio
- SILO N/A
- RNAZ N/A
- Revenue Growth
- SILO N/A
- RNAZ N/A
- 52 Week Low
- SILO $0.77
- RNAZ $2.66
- 52 Week High
- SILO $4.50
- RNAZ $66.33
- Technical
- Relative Strength Index (RSI)
- SILO 79.84
- RNAZ 30.32
- Support Level
- SILO $1.62
- RNAZ $2.90
- Resistance Level
- SILO $2.16
- RNAZ $3.50
- Average True Range (ATR)
- SILO 0.31
- RNAZ 0.42
- MACD
- SILO 0.10
- RNAZ 0.31
- Stochastic Oscillator
- SILO 43.37
- RNAZ 50.74
About SILO Silo Pharma Inc.
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders.
About RNAZ TransCode Therapeutics Inc.
TransCode Therapeutics Inc is a clinical-stage oncology company focused on treating metastatic disease. It is committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. The company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors which overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. In addition, TransCode is developing a portfolio of first-in-class RNA therapeutic candidates designed to overcome the challenges of RNA delivery and thus unlock therapeutic access to a variety of novel genetic targets that could be relevant to treating a variety of cancers.